Zacks: Fresenius SE (NASDAQ:FSNUY) Receives Consensus Recommendation of “Hold” from Brokerages
Fresenius SE (NASDAQ:FSNUY) has been given an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Zacks has also assigned Fresenius SE an industry rank of 53 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded Fresenius SE from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 21st.
Fresenius SE (NASDAQ FSNUY) traded up 2.59% on Friday, hitting $20.19. The stock had a trading volume of 14,406 shares. Fresenius SE has a 1-year low of $17.22 and a 1-year high of $22.30.
TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/13/zacks-fresenius-se-nasdaqfsnuy-receives-consensus-recommendation-of-hold-from-brokerages.html.
About Fresenius SE
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fresenius SE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE and related companies with MarketBeat.com's FREE daily email newsletter.